HRP20220595T1 - Prstenasti eterski derivati pirazolo[1,5-a]pirimidin-3-karboksamida - Google Patents
Prstenasti eterski derivati pirazolo[1,5-a]pirimidin-3-karboksamida Download PDFInfo
- Publication number
- HRP20220595T1 HRP20220595T1 HRP20220595TT HRP20220595T HRP20220595T1 HR P20220595 T1 HRP20220595 T1 HR P20220595T1 HR P20220595T T HRP20220595T T HR P20220595TT HR P20220595 T HRP20220595 T HR P20220595T HR P20220595 T1 HRP20220595 T1 HR P20220595T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- image
- group
- represented
- formula
- Prior art date
Links
- -1 Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide Chemical class 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 48
- 150000003839 salts Chemical class 0.000 claims 16
- 206010012289 Dementia Diseases 0.000 claims 11
- 208000010877 cognitive disease Diseases 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 230000013016 learning Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000002636 symptomatic treatment Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010054089 Depressive symptom Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001103 thalamus Anatomy 0.000 claims 1
- 208000018726 traumatic encephalopathy Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Claims (47)
1. Spoj, naznačen time, da je predstavljen formulom (I)
[image]
pri čemu
A se bira iz skupine Aa koju čine
[image]
pri čemu su gore navedene skupine supstituirane s jednim R5 i s jednim R6;
R1 se bira iz skupine R1a koju čine halogen, C1-3-alkil- i C3-6-cikloalkil-, pri čemu gore navedene skupine C1-3-alkil-, i C3-6-cikloalkil- mogu biti opcionalno supstituirane s 1 do 5 supstituenata koje se neovisno bira iz skupine koju čine halogen, NC- i HO-;
R2 se bira iz skupine R2a koju čine aril i heteroaril, pri čemu gore navedene skupine aril- i heteroaril- mogu biti opcionalno supstituirane s 1 do 5 supstituenata R4;
R3 se bira iz skupine R3a koju čine H- i C1-3-alkil-, pri čemu gore navedena skupina C1-3-alkil- može biti opcionalno supstituirana s 1 do 7 supstituenata koje se međusobno neovisno bira iz skupine koju čini halogen;
R4 se međusobno neovisno bira iz skupine R4a koju čine halogen, NC-, HO-,
C1-4-alkil- i C1-3-alkil-O-, pri čemu gore navedene skupine C1-4-alkil- i C1-3-alkil-O- mogu biti opcionalno supstituirane s 1 do 5 supstituenata koje se neovisno bira iz skupine koju čine HO- i F-;
R5 se bira iz skupine R5a koju čine H-, halogen, NC-, HO- i C1-3-alkil-, pri čemu gore navedena skupina C1-3-alkil- može biti opcionalno supstituirana s 1 do 5 supstituenata koje se neovisno bira iz skupine koju čine HO- i F- ili R5 i R6 zajedno tvore skupinu O=;
R6 se bira iz skupine R6a koju čine H-, halogen, NC-, HO- i C1-3-alkil-, pri čemu gore navedena skupina C1-3-alkil- može biti opcionalno supstituirana s 1 do 5 supstituenata koje se neovisno bira iz skupine koju čine HO- i F- ili R5 i R6 zajedno tvore skupinu O=;
ili njegova sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da
A se bira iz skupine Ab koju čine
[image]
pri čemu su gore navedene skupine supstituirane s jednim R5 i s jednim R6.
ili njegova sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da
A se bira iz skupine Ac koju čine
[image]
ili njegova sol.
4. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 3, naznačen time, da
R1 se bira iz skupine R1b koju čine F-, Cl-, C1-3-alkil- i C3-6-cikloalkil-, pri čemu gore navedene skupine C1-3-alkil- i C3-6-cikloalkil- mogu biti opcionalno supstituirane s 1 do 3 supstituenta koje se neovisno bira iz skupine koju čini F-,
ili njegova sol.
5. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 3, naznačen time, da
R1 se bira iz skupine R1c koju čine F-, H3C- i ciklopropil-,
ili njegova sol.
6. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 5, naznačen time, da
R2 se bira iz skupine R2b koju čine kinolinil, fenil i piridinil, pri čemu gore navedeni kinolin i skupine fenil- i piridil- mogu biti opcionalno supstituirani s 1 do 5 supstituenata R4,
ili njegova sol.
7. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 5, naznačen time, da
R2 se bira iz skupine R2c koju čine fenil i piridil, pri čemu gore navedene skupine fenil- i piridil- mogu biti opcionalno supstituirane s 1 do 2 supstituenata R4,
ili njegova sol.
8. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 7, naznačen time, da
R3 se bira iz skupine R3b koju čine H-, H3C-, F3C-, F2HC-, FH2C- i F3C-,
ili njegova sol.
9. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 8, naznačen time, da
R4 se međusobno neovisno bira iz skupine R4b koju čine halogen, C1-4-alkil- i C1-3-alkil-O-, pri čemu gore navedene skupine C1-4-alkil- i C1-3-alkil-O- mogu biti opcionalno supstituirane s 1 do 5 supstituenata koje se neovisno bira iz skupine koju čine HO-, i F-,
ili njegova sol.
10. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 9, naznačen time, da
R5 se bira iz skupine R5b koju čine H-, HO- i C1-2-alkil-, pri čemu gore navedena skupina C1-2-alkil- može biti opcionalno supstituirana s 1 do 5 F-, ili R5 i R6 zajedno tvore skupinu O=,
ili njegova sol.
11. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 10, naznačen time, da
R6 se bira iz skupine R6b koju čine H- i C1-2-alkil-, pri čemu gore navedena skupina C1-2-alkil- može biti opcionalno supstituirana s 1 do 5 F-, ili R5/R6 zajedno tvore skupinu O=,
ili njegova sol.
12. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da se bira iz skupine koju čine
[image]
[image]
[image]
[image]
[image]
[image]
[image]
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
15. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
16. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
17. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
18. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
19. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
20. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
21. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
22. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
23. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
24. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
25. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
26. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
27. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
28. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
29. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
30. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
31. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
32. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
33. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
34. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
35. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
36. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
37. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
38. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
39. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
40. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
41. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
42. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljen formulom:
[image]
43. Farmaceutski prihvatljiva sol, naznačena time, da je od bilo kojeg od spojeva u skladu s patentnim zahtjevima 1 do 42.
44. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 42, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je namijenjen uporabi kao medikament.
45. Farmaceutski pripravci, naznačeni time, da sadrže najmanje jedan spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 42, ili njegovu farmaceutski prihvatljivu sol, zajedno s jednim ili više farmaceutski prihvatljivih nosača.
46. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 42, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 45, naznačen time, da je namijenjen uporabi u sprečavanju ili liječenju (1) poremećaja koji sadrže simptom kognitivne deficijencije; (2) organskih, uključujući simptomatskih, mentalnih poremećaja, demencije; (3) mentalne zaostalosti; (4) poremećaja raspoloženja (afektivnih poremećaja); (5) neurotskih, poremećaja povezanih sa stresom i somatoformnih poremećaja, uključujući anksiozne poremećaje; (6) poremećaja ponašanja i emocija, koji obično počinju u djetinjstvu i adolescenciji, sindroma hiperaktivnosti uz nedostatak pažnje (ADHD) i poremećaja autističnog spektra; (7) poremećaja psihološkog razvoja, razvojnih poremećaja vještina učenja; (8) shizofrenije i drugih psihotičnih poremećaja; (9) poremećaja osobnosti i ponašanja kod odraslih osoba; (10) mentalnih i poremećaja ponašanja uzrokovanih uporabom psihoaktivnih tvari; (11) ekstrapiramidalnih i poremećaja kretanja; (12) epizodnih i paroksizmalnih poremećaja, epilepsije; (13) sistemnih atrofija koje primarno utječu na središnji živčani sustav, ataksiju; (14) bihevioralnih sindroma povezanih s fiziološkim poremećajima i fizičkim čimbenicima; (15) spolne disfunkcije koju čini prekomjerni spolni nagon; (16) činjeničnih poremećaja; (17) liječenju, ublažavanju i/ili sprečavanju kognitivnog poremećaja povezanog s percepcijom, koncentracijom, spoznajom, učenjem ili pamćenjem; (18) liječenju, ublažavanju i/ili sprečavanju kognitivnog poremećaja povezanog s poremećajima učenja i pamćenja uzrokovanim starenjem; (19) gubitka pamćenja uzrokovanog starenjem; (20) vaskularne demencije; (21) kraniocerebralne traume; (22) inzulta; (23) demencije do koje dolazi nakon inzulta (postinzultne demencije); (24) posttraumatske demencije; (25) općih poremećaja koncentracije; (26) poremećaja koncentracije kod djece koja imaju probleme s učenjem i pamćenjem; (27) Alzheimerove bolesti; (28) demencije s Lewyjevim tjelešcima; (29) demencije s degeneracijom čeonih režnjeva; uključujući Pickov sindrom; (30) Parkinsonove bolesti; (31) progresivne nuklearne paralize; (32) demencije s kortikobazalnom degeneracijom; (33) amiotrofne lateralne skleroze (ALS); (34) Huntingtonove bolesti; (35) multiple skleroze; (36) degeneracije talamusa; (37) Creutzfeld-Jacobove demencije; (38) demencije uzrokovane HIV-om; (38) shizofrenije s demencijom ili Korsakovljeve psihoze; (39) poremećaja spavanja; (40) bipolarnog poremećaja; (41) metaboličkog sindroma; (42) pretilosti; (43) dijabetesa melitusa; (44) hiperglikemije; (45) dislipidemije; (46) poremećenog podnošenja glukoze; (47) bolesti testisa, mozga, tankog crijeva, skeletnih mišića, srca, pluća, prsne žlijezde ili slezene; (48) bolnih poremećaja; (49) neuropsihijatrijskih simptoma (primjerice depresivnih simptoma kod Alzheimerove bolesti); (50) mješovite demencije; (51) kognitivnog poremećaja kod shizoafektivnog poremećaja; (52) kognitivnog poremećaja kod bipolarnog poremećaja; (53) kognitivnog poremećaja kod velikog depresivnog poremećaja i (54) kognitivnog poremećaja povezanog s shizofrenijom; (55) simptomatskom liječenju Alzheimerove bolesti; (56) simptomatskom liječenju prodromalne i blage do umjerene Alzheimerove bolesti; (57) kognitivnog poremećaja kod Huntingtonove bolesti; (58) kognitivnog poremećaja kod poremećaja autističnog spektra; (59) kognitivnog poremećaja kod Parkinsonove bolesti; (60) kognitivnog poremećaja nakon inzulta (postinzultne demencije); (61) kognitivnog poremećaja kod vaskularne demencije.
47. Spoj u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 42, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 45, koji je namijenjen uporabi u skladu s patentnim zahtjevom 46, naznačen time, da se spoj primjenjuje uz druge aktivne tvari namijenjene liječenju ili sprečavanju bolesti i stanja u skladu s patentnim zahtjevom 46.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15189600.8A EP3156405A1 (en) | 2015-10-13 | 2015-10-13 | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| PCT/EP2016/074380 WO2017064082A1 (en) | 2015-10-13 | 2016-10-12 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide |
| EP16788047.5A EP3362453B1 (en) | 2015-10-13 | 2016-10-12 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220595T1 true HRP20220595T1 (hr) | 2022-06-10 |
Family
ID=54293164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220595TT HRP20220595T1 (hr) | 2015-10-13 | 2016-10-12 | Prstenasti eterski derivati pirazolo[1,5-a]pirimidin-3-karboksamida |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10023575B2 (hr) |
| EP (2) | EP3156405A1 (hr) |
| JP (1) | JP6626965B2 (hr) |
| KR (1) | KR102611558B1 (hr) |
| CN (2) | CN114181213A (hr) |
| AU (1) | AU2016338602B2 (hr) |
| BR (1) | BR112018004347B1 (hr) |
| CA (1) | CA3001929C (hr) |
| CL (1) | CL2018000856A1 (hr) |
| CO (1) | CO2018003756A2 (hr) |
| DK (1) | DK3362453T3 (hr) |
| EA (1) | EA035350B1 (hr) |
| ES (1) | ES2912223T3 (hr) |
| HK (1) | HK1254651A1 (hr) |
| HR (1) | HRP20220595T1 (hr) |
| IL (1) | IL258070B (hr) |
| LT (1) | LT3362453T (hr) |
| MA (1) | MA42988B1 (hr) |
| MX (1) | MX2018004524A (hr) |
| MY (1) | MY195169A (hr) |
| NZ (1) | NZ740119A (hr) |
| PE (2) | PE20190778A1 (hr) |
| PH (1) | PH12018500796A1 (hr) |
| PL (1) | PL3362453T3 (hr) |
| PT (1) | PT3362453T (hr) |
| RS (1) | RS63218B1 (hr) |
| SA (1) | SA518391334B1 (hr) |
| SI (1) | SI3362453T1 (hr) |
| UA (1) | UA124576C2 (hr) |
| WO (1) | WO2017064082A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3156405A1 (en) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| RU2671964C1 (ru) * | 2017-08-30 | 2018-11-08 | Сиа Эволед | Пиразоло[1,5-а]пиримидинкарбоксилаты гадолиния и органические светодиоды на их основе |
| US11498928B2 (en) | 2019-01-18 | 2022-11-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as Mcl-1 inhibitors |
| CN110339197A (zh) * | 2019-06-24 | 2019-10-18 | 中山大学 | 一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| EP1572113B1 (en) * | 2002-08-26 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| EA010424B1 (ru) | 2003-12-16 | 2008-08-29 | Пфайзер Продактс Инк. | ПИРИДО[2,3-d]ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| WO2005087751A2 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| CN101133057B (zh) | 2004-09-02 | 2011-03-09 | 尼科梅德有限责任公司 | 三唑并酞嗪化合物 |
| EP1874775B1 (en) | 2005-01-05 | 2012-10-10 | Nycomed GmbH | Triazolophthalazines as pde2-inhibitors |
| EP1836207B1 (en) | 2005-01-05 | 2012-10-10 | Nycomed GmbH | Triazolophthalazines as pde2-inhibitors |
| BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| CN101296699B (zh) * | 2005-10-21 | 2013-01-02 | 田边三菱制药株式会社 | 吡唑并[1,5-a]嘧啶化合物 |
| AR056876A1 (es) | 2005-10-21 | 2007-10-31 | Tanabe Seiyaku Co | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares |
| WO2007121319A2 (en) | 2006-04-14 | 2007-10-25 | University Of California | Compostions and methods for determining and predicting treatment responses for depression and anxiety |
| TWI419889B (zh) * | 2006-07-05 | 2013-12-21 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔１，５-ａ〕嘧啶化合物 |
| AR061793A1 (es) * | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| CN102271515B (zh) * | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
| EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| EP2763989A1 (en) | 2011-09-09 | 2014-08-13 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2014025651A1 (en) * | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
| WO2015012328A1 (ja) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3061754A4 (en) | 2013-10-23 | 2017-03-22 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3087060B1 (en) | 2013-12-23 | 2020-05-13 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| EP3156405A1 (en) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| JP2017095366A (ja) * | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
-
2015
- 2015-10-13 EP EP15189600.8A patent/EP3156405A1/en not_active Ceased
-
2016
- 2016-10-12 CN CN202111335164.6A patent/CN114181213A/zh active Pending
- 2016-10-12 EA EA201890922A patent/EA035350B1/ru not_active IP Right Cessation
- 2016-10-12 DK DK16788047.5T patent/DK3362453T3/da active
- 2016-10-12 JP JP2018518960A patent/JP6626965B2/ja active Active
- 2016-10-12 MY MYPI2018000484A patent/MY195169A/en unknown
- 2016-10-12 AU AU2016338602A patent/AU2016338602B2/en active Active
- 2016-10-12 CA CA3001929A patent/CA3001929C/en active Active
- 2016-10-12 PT PT167880475T patent/PT3362453T/pt unknown
- 2016-10-12 PE PE2018000540A patent/PE20190778A1/es unknown
- 2016-10-12 PE PE2018001274A patent/PE20181447A1/es unknown
- 2016-10-12 CN CN201680059328.8A patent/CN108137602B/zh active Active
- 2016-10-12 HR HRP20220595TT patent/HRP20220595T1/hr unknown
- 2016-10-12 MX MX2018004524A patent/MX2018004524A/es active IP Right Grant
- 2016-10-12 SI SI201631526T patent/SI3362453T1/sl unknown
- 2016-10-12 NZ NZ740119A patent/NZ740119A/en unknown
- 2016-10-12 KR KR1020187013541A patent/KR102611558B1/ko active IP Right Grant
- 2016-10-12 LT LTEPPCT/EP2016/074380T patent/LT3362453T/lt unknown
- 2016-10-12 ES ES16788047T patent/ES2912223T3/es active Active
- 2016-10-12 US US15/291,316 patent/US10023575B2/en active Active
- 2016-10-12 MA MA42988A patent/MA42988B1/fr unknown
- 2016-10-12 UA UAA201804978A patent/UA124576C2/uk unknown
- 2016-10-12 BR BR112018004347-8A patent/BR112018004347B1/pt active IP Right Grant
- 2016-10-12 WO PCT/EP2016/074380 patent/WO2017064082A1/en active Application Filing
- 2016-10-12 RS RS20220468A patent/RS63218B1/sr unknown
- 2016-10-12 EP EP16788047.5A patent/EP3362453B1/en active Active
- 2016-10-12 PL PL16788047.5T patent/PL3362453T3/pl unknown
-
2018
- 2018-01-09 US US15/865,695 patent/US10479794B2/en active Active
- 2018-03-13 IL IL258070A patent/IL258070B/en active IP Right Grant
- 2018-04-03 CL CL2018000856A patent/CL2018000856A1/es unknown
- 2018-04-09 CO CONC2018/0003756A patent/CO2018003756A2/es unknown
- 2018-04-11 SA SA518391334A patent/SA518391334B1/ar unknown
- 2018-04-13 PH PH12018500796A patent/PH12018500796A1/en unknown
- 2018-10-24 HK HK18113618.5A patent/HK1254651A1/zh unknown
-
2019
- 2019-10-14 US US16/600,965 patent/US10875867B2/en active Active
-
2020
- 2020-10-20 US US17/075,091 patent/US11691977B2/en active Active
-
2023
- 2023-05-19 US US18/320,264 patent/US20230286993A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220595T1 (hr) | Prstenasti eterski derivati pirazolo[1,5-a]pirimidin-3-karboksamida | |
| AU2014241759B2 (en) | Substituted naphthyridine and quinoline compounds as MAO inhibitors | |
| CO2019014047A2 (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios | |
| UY37013A (es) | 2-fenil-3-(piperazinometil)imidazopiridinas sustituidas y su uso | |
| UY37328A (es) | Compuestos diazaheterobicíclicos sustituidos y su uso | |
| JP2015523406A5 (hr) | ||
| HRP20221518T1 (hr) | Diaril makrociklični spojevi kao modulatori protein kinaza | |
| EA201201664A1 (ru) | Производные 6-циклоалкил-1,5-дигидропипазоло[3,4-d]пиримидин-4-она и их применение в качестве ингибиторов pde9a | |
| BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
| JP2014506890A5 (hr) | ||
| HRP20201379T1 (hr) | Antibakterijski spojevi koji imaju široki spektar djelovanja | |
| JP2017522340A5 (hr) | ||
| JP2015521642A5 (hr) | ||
| Chhabria et al. | Design, synthesis and antimycobacterial activity of some novel imidazo [1, 2-c] pyrimidines | |
| CN114761005A (zh) | 医学认知治疗 | |
| CA2960386A1 (en) | Mao-b inhibitors and rehabilitation | |
| WO2015153971A1 (en) | Methods of treating sleep disorders associated with neurodegenerative diseases | |
| Manjunatha et al. | Recurrent opisthotonus in catatonia: An atypical presentation | |
| FI3541784T3 (fi) | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina | |
| Lan et al. | Nursing Experience of Using Mirror Visual Feedback for a Schizophrenia Patient With Visual Hallucinations | |
| Yuvaraj et al. | Effect of Saraswatarishta on sleep deprivation induced behavioral changes in mice. | |
| Paik et al. | Motor learning: basic concept and theories | |
| Kutashov et al. | THERAPY of CHILDREN'S UNEASINESS in the FAMILY | |
| Shetty | The Effect of Race on Determining the Treatment Response to Serotonergic Antidepressant Drugs in Intellectually Disabled Adults | |
| Kamis | Drug toxicity and atypical NMS symptoms: case report |